5 results on '"Philippa Musoke"'
Search Results
2. A hospital-based birth defects surveillance system in Kampala, Uganda
- Author
-
Robert Serunjogi, Doreen Birabwa-Male, Linda Barlow-Mosha, Margaret Achom Okwero, Dhelia M. Williamson, Ayoub Kakande, Joyce Namale-Matovu, Jolly Nankunda, Philippa Musoke, Diana Valencia, Daniel Mumpe-Mwanja, and Jesca Nsungwa-Sabiiti
- Subjects
Adult ,Male ,medicine.medical_specialty ,Congenital anomalies ,Reproductive medicine ,Abortion ,lcsh:Gynecology and obstetrics ,Risk Assessment ,Congenital Abnormalities ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,medicine ,Prevalence ,Humans ,Uganda ,030212 general & internal medicine ,lcsh:RG1-991 ,Birth prevalence ,Retrospective Studies ,0303 health sciences ,business.industry ,Obstetrics ,Incidence (epidemiology) ,Incidence ,030305 genetics & heredity ,Infant, Newborn ,Obstetrics and Gynecology ,Gestational age ,Hospital-based surveillance ,medicine.disease ,Hospital Records ,Hospitals ,3. Good health ,Birth defects ,Hypospadias ,Population Surveillance ,Electronic data ,Female ,business ,Imperforate anus ,Research Article ,Follow-Up Studies - Abstract
BackgroundIn 2010, the World Health Assembly passed a resolution calling upon countries to prevent birth defects where possible. Though birth defects surveillance programs are an important source of information to guide implementation and evaluation of preventive interventions, many countries that shoulder the largest burden of birth defects do not have surveillance programs. This paper shares the results of a hospital-based birth defects surveillance program in Uganda which, can be adopted by similar resource-limited countries.MethodsAll informative births, including live births, stillbirths and spontaneous abortions; regardless of gestational age, delivered at four selected hospitals in Kampala from August 2015 to December 2017 were examined for birth defects. Demographic data were obtained by midwives through maternal interviews and review of hospital patient notes and entered in an electronic data collection tool. Identified birth defects were confirmed through bedside examination by a physician and review of photographs and a narrative description by a birth defects expert. Informative births (live, still and spontaneous abortions) with a confirmed birth defect were included in the numerator, while the total informative births (live, still and spontaneous abortions) were included in the denominator to estimate the prevalence of birth defects per 10,000 births.ResultsThe overall prevalence of birth defects was 66.2/10,000 births (95% CI 60.5–72.5). The most prevalent birth defects (per 10,000 births) were: Hypospadias, 23.4/10,000 (95% CI 18.9–28.9); Talipes equinovarus, 14.0/10,000 (95% CI 11.5–17.1) and Neural tube defects, 10.3/10,000 (95% CI 8.2–13.0). The least prevalent were: Microcephaly, 1.6/10,000 (95% CI 0.9–2.8); Microtia and Anotia, 1.6/10,000 (95% CI 0.9–2.8) and Imperforate anus, 2.0/10,000 (95% CI 1.2–3.4).ConclusionA hospital-based surveillance project with active case ascertainment can generate reliable epidemiologic data about birth defects prevalence and can inform prevention policies and service provision needs in low and middle-income countries.
- Published
- 2019
3. Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy
- Author
-
Adeodata Kekitiinwa, Kusum Nathoo, Victor Musiime, Patricia Nahirya-Ntege, Sabrina Bakeera-Kitaka, A. Sarah Walker, Angela M. Crook, Margaret J. Thomason, Peter Mugyenyi, Mutsa Bwakura-Dangarembizi, Andrew J. Prendergast, Anna Turkova, Philippa Musoke, Diana M. Gibb, and Paula Munderi
- Subjects
0301 basic medicine ,Male ,Zimbabwe ,Pediatrics ,medicine.medical_specialty ,Tuberculosis ,Randomization ,030106 microbiology ,Population ,HIV Infections ,Comorbidity ,Incident tuberculosis ,03 medical and health sciences ,0302 clinical medicine ,Anti-Infective Agents ,Risk Factors ,Trimethoprim, Sulfamethoxazole Drug Combination ,Medicine ,Humans ,Mass Screening ,Uganda ,030212 general & internal medicine ,education ,Child ,Mass screening ,Proportional Hazards Models ,Medicine(all) ,Pediatric ,education.field_of_study ,business.industry ,Proportional hazards model ,Incidence (epidemiology) ,Incidence ,Hazard ratio ,HIV ,Infant ,General Medicine ,medicine.disease ,3. Good health ,Antiretroviral therapy ,Child, Preschool ,Female ,business ,Research Article - Abstract
Background There are few data on tuberculosis (TB) incidence in HIV-infected children on antiretroviral therapy (ART). Observational studies suggest co-trimoxazole prophylaxis may prevent TB, but there are no randomized data supporting this. The ARROW trial, which enrolled HIV-infected children initiating ART in Uganda and Zimbabwe and included randomized cessation of co-trimoxazole prophylaxis, provided an opportunity to estimate the incidence of TB over time, to explore potential risk factors for TB, and to evaluate the effect of stopping co-trimoxazole prophylaxis. Methods Of 1,206 children enrolled in ARROW, there were 969 children with no previous TB history. After 96 weeks on ART, children older than 3 years were randomized to stop or continue co-trimoxazole prophylaxis; 622 were eligible and included in the co-trimoxazole analysis. Endpoints, including TB, were adjudicated blind to randomization by an independent endpoint review committee (ERC). Crude incidence rates of TB were estimated and potential risk factors, including age, sex, center, CD4, weight, height, and initial ART strategy, were explored in multivariable Cox proportional hazards models. Results After a median of 4 years follow-up (3,632 child-years), 69 children had an ERC-confirmed TB diagnosis. The overall TB incidence was 1.9/100 child-years (95 % CI, 1.5–2.4), and was highest in the first 12 weeks following ART initiation (8.8/100 child-years (5.2–13.4) versus 1.2/100 child-years (0.8–1.6) after 52 weeks). A higher TB risk was independently associated with younger age (
- Published
- 2016
4. Epidemiology of tuberculosis in children in Kampala district, Uganda, 2009–2010; a retrospective cross-sectional study
- Author
-
Moorine Penninah Sekadde, Irene Lubega, Frank Mugabe, Deus Lukoye, Eric Wobudeya, and Philippa Musoke
- Subjects
Male ,medicine.medical_specialty ,Pediatrics ,Tuberculosis ,Adolescent ,Cross-sectional study ,Population ,HIV Infections ,Poverty Areas ,Epidemiology ,medicine ,Humans ,Uganda ,education ,Child ,Tuberculosis, Pulmonary ,Retrospective Studies ,education.field_of_study ,Under-five ,business.industry ,Coinfection ,Incidence (epidemiology) ,Incidence ,Public Health, Environmental and Occupational Health ,Infant ,Retrospective cohort study ,medicine.disease ,Cross-Sectional Studies ,Child, Preschool ,Female ,Biostatistics ,business ,Demography ,Research Article - Abstract
Background The global tuberculosis (TB) estimate in 2011 was 500,000 cases among children under 15 years representing 5.7 % of all cases and 64, 000 deaths among HIV negative children representing 6.5 % of the total deaths. In Uganda, the child TB cases reported in 2012 made up less than 3 % of the total cases while recent modelling estimates it at 15–20 % of adult cases. Mapping of these cases in Kampala district most especially for the children under five years would reflect recent transmission in the various communities in the district. We therefore conducted a retrospective study of reported child TB cases in Kampala district Uganda for 2009–2010 to provide an estimate of child TB incidence and map the cases. Methods This was a retrospective cross-sectional study on data collected from the health unit TB registers in the five divisions of Kampala district, Uganda. The data was a starting point in preparation for a TB Vaccine study in children. The extracted data spanned a period from 1st January 2009 to 31st December 2010. The projected population of children below 15 years was 637,922 in 2009 and 744,750 in 2010 for Kampala district. We based our projections on the National Bureau of Statistics most recent census report of 2002 before the study duration while assuming a population growth rate of 3.7 % each year. We captured the data into EPI DATA 3.1 and analysed it using STATA version 12. Results We accessed 15,499 records and analysed 1167 records that were of children below 15 years old. The child TB cases represented 7.5 % (7.3 in 2009 & 7.6 % in 2010) of all the registered cases in Kampala district. The females were 47 % and the median age was 4 years (IQR 1, 10). The percent of children less than 5 years old was 54 %. The percent of pulmonary TB cases was 89 % (1041/1167) with 15 % smear positive. The proportion of extra-pulmonary TB cases was 11 % (126/1167). Among those that tested for HIV, 60 % (359/620) had test results available with an HIV co-infection rate of 47 % (168/359). Antiretroviral treatment uptake was 24 % among the co-infected. The incidence of child TB in Kampala was 56 (95 % CI 50–62) per 100,000 in 2009 and 44 (95 % CI 40–49) per 100,000 in 2010. Most of the TB cases (60 % (410/685)) in Kampala live in slum areas. Conclusion There was a higher child TB incidence of 56 per 100,000 in 2009 compared with 44 per 100,000 in 2010. The percentage of child TB cases was much higher at 7.5 % of all the reported TB cases than the WHO reported national average. For the review period, the TB cases clustered in particular slums in Kampala district.
- Published
- 2015
5. Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study
- Author
-
Linda Barlow-Mosha, Michael Mubiru, Danstan Bagenda, Patrick Ajuna, Thorkild Tylleskär, Philippa Musoke, Peter Mudiope, and Mary Glenn Fowler
- Subjects
Male ,medicine.medical_specialty ,Population ,HIV Infections ,Growth ,Virus ,Cohort Studies ,Immune system ,Internal medicine ,Antiretroviral Therapy, Highly Active ,Medical disciplines: 700::Clinical medical disciplines: 750::Communicable diseases: 776 [VDP] ,medicine ,Humans ,Uganda ,Pediatrics, Perinatology, and Child Health ,education ,Prospective cohort study ,Child ,education.field_of_study ,business.industry ,lcsh:RJ1-570 ,lcsh:Pediatrics ,Viral Load ,Confidence interval ,CD4 Lymphocyte Count ,Treatment Outcome ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Immunology ,HIV-1 ,RNA, Viral ,Female ,business ,Body mass index ,Viral load ,Cohort study ,Research Article - Abstract
Background Scale up of paediatric antiretroviral therapy in resource limited settings continues despite limited access to routine laboratory monitoring. We documented the weight and height responses in HIV infected Ugandan children on highly active antiretroviral therapy and determined clinical factors associated with successful treatment outcomes. Methods A prospective cohort of HIV infected children were initiated on HAART and followed for 48 weeks. Body mass index for age z scores(BAZ), weight and height-for-age z scores (WAZ & HAZ) were calculated: CD4 cell % and HIV-1 RNA were measured at baseline and every 12 weeks. Treatment outcomes were classified according to; both virological and immunological success (VS/IS), virological failure and immunological success (VF/IS). virological success and immunological failure (VS/IF) and both virological and immunological failure (VF/IF). Results From March 2004 until May 2006, 124 HIV infected children were initiated on HAART. The median age (IQR) was 5.0 years (2.1 - 7.0) and 49% (61/124) were female. The median [95% confidence interval (CI)] BAZ, WAZ and HAZ at baseline were 0.29 (-2.9, -1.2), -1.2 (-2.1, -0.5) and -2.06 (-2.9, -1.2) respectively. Baseline median CD4 cell % and log10 HIV-1 RNA were; 11.8% (7.5-18.0) and 5.6 (5.2-5.8) copies/ml. By 48 weeks, mean WAZ and HAZ in the VF/IS group, which was younger, increased from - 0.98 (SD 1.7) to + 1.22 (SD 1.2) and from -1.99 (1.7) to + 0.76 (2.4) respectively. Mean increase in WAZ and HAZ in the VS/IF group, an older group was modest, from -1.84 (1.3) to - 0.41 (1.2) and -2.25 (1.2) to -1.16 (1.3) respectively. Baseline CD4 cell % [OR 6.97 95% CI (2.6 -18.6)], age [OR 4.6 95% CI (1.14 -19.1)] and WHO clinical stage [OR 3.5 95%CI (1.05 -12.7)] were associated with successful treatment outcome. Conclusions HIV infected Ugandan children demonstrated a robust increase in height and weight z scores during the first 48 weeks of HAART, including those who failed to completely suppress virus. Older children initiating HAART with severe immune suppression were less likely to achieve a successful treatment outcome. These data emphasize the importance of initiating HAART early to ensure adequate immune and growth responses.
- Published
- 2010
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.